PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents yoy growth at least 1.5x AVXL's 6.17%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Cash + STI yoy ≥ 1.5x AVXL's 6.17%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
≥ 1.5x AVXL's 5.52%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-6.11%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-0.83%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
67.39%
≥ 1.5x AVXL's 5.51%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-6.24%
Less than half of AVXL's -30.34%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Similar yoy changes to AVXL's -77.87%. Walter Schloss finds parallel near-term liability trends.
-14.04%
Less than half of AVXL's -31.38%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Less than half of AVXL's -31.38%. David Dodd sees far fewer liability expansions relative to competitor.
36.75%
Above 1.5x AVXL's 1.92%. Michael Burry suspects heavy new equity expansion or dilution.
-4.17%
Similar yoy to AVXL's -4.36%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.37%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
105.08%
≥ 1.5x AVXL's 9.15%. David Dodd sees stronger capital base growth than competitor.
67.39%
≥ 1.5x AVXL's 5.51%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Above 1.5x AVXL's -6.17%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.